Collectively, these data highlight the association between necroptosis machinery and glioma aggressiveness, suggesting a pivotal role for RIPK1, RIPK3, and MLKL in disease progression and clinical outcome. The gene discussed is RIPK1; the disease is central nervous system cancer.